par Curigliano, Giuseppe;Locatelli, Marzia;Fumagalli, Luca;Brollo, Janaina;Munzone, Elisabetta;Nolé, Franco;Criscitiello, Carmen 
;Goldhirsch, Aron
Référence Expert opinion on investigational drugs, 21, 2, page (191-204)
Publication Publié, 2012-02
;Goldhirsch, AronRéférence Expert opinion on investigational drugs, 21, 2, page (191-204)
Publication Publié, 2012-02
Article révisé par les pairs
| Résumé : | The choice of adjuvant treatments for women with breast cancer is based on several features that take into account the heterogeneity of the disease. Questions raised during the decision process include the following: i) What leads to the use of endocrine therapy? ii) What leads to the use of anti-HER2 therapy? iii) What justifies the use of chemotherapy? |
